Business
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
Response at Day 29 was associated with 72% overall survival at 12 months and high rates of progression-free survival 79% of responders maintained or achieved
About this update from Equillium, Inc.
[{"type":"text","content":"\nResponse at Day 29 was associated with 72% overall survival at 12 months and high rates of progression-free survival\n\n79% of responders maintained or achieved a complete response through at least 6 months\n\nResponders were able to taper corticosteroids by 73% at Day 29 and 96% at 6 months\n\nClinical efficacy of itolizumab associated with higher itolizumab serum concentrations after a single dose\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced two oral presentations at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation. The presentations include new findings demonstrating durability of clinical response out to one year for patients with high-risk acute graft-versus-host disease (aGVHD) that were treated with itolizumab in the EQUATE study. Clinical data were presented by Corey Cutler, M.D., associate professor of medicine, Dana Farber Cancer Institute, Harvard Medical School.\n\n“These extended twelve-month findings add to the critical mass of data indicating the potential clinical value of itolizumab for patients with high-risk aGVHD initiating therapy with corticosteroids,” said Dr. Cutler. “In addition to these rapid and durable responses, I’m particularly encouraged by a clinically meaningful reduction in the use of corticosteroids and that response at Day 29 was associated with 72 percent overall survival at 12 months, as well as high rates of progression free survival.”\n\nData demonstrated that across all dose cohorts Day 29 complete response (CR) rate was 52%, overall response rate (ORR) was 64% and that the highest Day 29 CR rate of 61% was achieved in subjects treated with itolizumab within 72 hours of starting systemic corticosteroids. Patients who responded to itolizumab treatment had clinically meaningful reductions in steroid administration during the evaluation period with a median reduction in steroid use of 73% by Day 29 and 96% by 6 months.\n\n“As we continue to collect data from the EQUATE study, we see more evidence of the association between itolizumab treatment and rapid and durable decreases in cell surface CD6, supporting itolizumab’s mechanism of action,” said Steve...